Osteonecrosis of the jaws and bisphosphonate therapy

Journal of Dental Research

Volumn 86, Issue 11, 2007, Pages 1013-1021

  Ruggiero, S L ^a,b   Drew, S J ^b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b New York Center for Orthognathic and Maxillofacial Surgery   (United States)

Author keywords

Bisphosphonate; Bone; BRONJ; Jaw; Mandible; Osteonecrosis; Osteoporosis

Indexed keywords

ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; BONE TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; MULTIPLE MYELOMA; PATHOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 36549026045     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910708601101     Document Type: Article

References (67)

1. Abrams HL, Spiro R, Goldstein N (1950). Metastases in carcinoma. Analysis of 1000 autopsied cases. Cancer 3:74-85.
2. ADA (2006). Report of the Council of Scientific Affairs. Expert panel recommendations: dental management of patients on oral bisphosphonate therapy. American Dental Association. June 2006. http://www.ada.org/prof/resources/ topics/osteonecrosis.asp
3. American Association of Endodontists (2005). Position statement on endodontic implications of bisphosphonate-associated osteonecrosis of the jaws, http://www.aae.org/dentalpro/guidelines.htm.
4. American Association of Oral and Maxillofacial Surgeons (2007). Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 65:369-376.
5. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. (2006). Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945-952.
6. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. (1996). Efficacy of Pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:484-493.
7. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. (1998). Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602.
8. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. (2002). American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736.
9. Bilezikian JP (2006). Osteonecrosis of the jaw-Do bisphosphonates pose a risk? N Engl J Med 355:2278-2281.
10. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
11. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. (2006). Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc 296:2927-2938.
12. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. (2004). Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199.
13. Cairo AM, Barbarano LA, Andriani A, D'Avanzo G, Nichelatti M, Gaglioti D, et al. (2005). Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience (AAOMS abstract). Blood 106:5152.
14. Cheng A, Mavrokokki A, Carter G, Stein B, Fazzalari NL, Wilson DF, et al. (2005). The dental implications of bisphosphonates and bone disease. Aust Dent J Med 50(Suppl):S4-S13.
15. Chesnut C, Majumdar S, Gardner J, Shields A, Newitt DC, Erickson E, et al. (2001). Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Adv Exp Med Biol 496:95-97.
16. Clain A (1985). Secondary malignant disease of bone. Br J Cancer 19:15-29.
17. Coleman RE, Rubens RD (1987). The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66.
18. Colon-Emeric CS (2006). Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing (editorial). J Am Med Assoc 296:2968-2969.
19. Conte P, Coleman R (2004). Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 31:59-63.
20. Deftos LJ (2005). Treatment of Paget's disease - taming the wild osteoclast. N Engl J Med 353:872-875.
21. Dimopoulos M, Kastritis E, Moulopoulos LA, Melakopoulos I, Anagnostopoulos A, Gika D, et al. (2005). The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate (abstract). Blood 106:637.
22. Durie BGM, Katz M, Crowley J (2005). Osteonecrosis of the jaw and bisphosphonates (Letter). N Engl J Med 353:99-102.
23. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS (2002). Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330.
24. Gallucci C, Agrillo A, Iannetti G, Foà R, Petrucci M (2005). Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients (abstract). Blood 106:3460.
25. Gibbs SD, O'Grady J, Seymour JF, Prince HM (2005). Bisphosphonateinduced osteonecrosis of the jaws requires early detection and intervention. Med J Aust 183:549-550.
26. Glass DA II, Patel MS, Karsenty G (2003). A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med 349:2479-2480.
27. Greenberg MS (2004). Intravenous bisphosphonates and osteonecrosis (editorial). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93:259-260.
28. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, et al. (2002). Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31:659-679.
29. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391.
30. Hoff AO, Toth BB, Altundag K, Guarnieri V, Adamus A, Nooka AK, et al. (2006). Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract). J Clin Oncol 24:8528. http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528
31. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. (1996). Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 335:1785-1792.
32. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. (1998). Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. J Clin Oncol 16:2038-2044.
33. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich MD, Ross P, et al. (1998). Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338:485-492.
34. Kanis JA (1995). Bone and cancer: pathophysiology and treatment of metastases. Bone 17(Suppl):101S-105S.
35. Katz H (2005). Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod 31:831-834.
36. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Golbach KL, Hayman SR, et al. (2006). Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053.
37. Lerner UH (2006), Bone remodeling in post-menopausal osteoporosis. J Dent Res 85:584-595.
38. Mrx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575.
39. Mavrokokki T, Cheng A, Stein B, Goss A (2007). Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 3:415-423.
40. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. (2001). Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340.
41. Mehrotra B, Ruggiero SL (2005). Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update (abstract). Blood 106:291.
42. Mehrotra B, Nissel-Horowitz S, Ruggiero SL, Sheth M, Vinarsky M, et al. (2003). Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report (abstract). Proc Am Soc Clin Oncol 22:195.
43. Melo MD, Obeid G (2005). Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. J Am Dent Assoc 136:1675-1681.
44. Michaelson MD, Smith MR (2005). Bisphosphonates for the treatment and prevention of bone metastases. J Clin Oncol 23:8219-8224.
45. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005a). Managing the care of patients with bisphosphonate-associated osteonecrosis. JAm Dent Assoc 136:1658-1668.
46. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005b). Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 104:83-93.
47. Miller P, Roux C, McClung M, Watts N, Genant H, Adami S, et al. (1999). Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Arthritis Rheum 42(Suppl 9):S287-S295.
48. Mundy GR (1987). Bone resorption and turnover in health and disease. Sone 8(Suppl 1):S9-S16.
49. Odvina CV, Zerwekh JE, Rao DS, Mahlouf N, Gottschalk FA, Pak CY (2005). Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
50. Office of the Surgeon General (2004). Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services.
51. Ott SM (2005). Long-term safety of bisphosphonates (editorial). J Clin Endocrinol Metab 90:1897-1899.
52. Pozzi S, Marcheselli R, Sacchi S, Quarta G, Musto P, Caparrotti G, et al. (2005). Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw (abstract). Blood 106:5057.
53. Purcell PM, Boyd IW (2005). Bisphosphonates and osteonecrosis of the jaw. Med JAust 182:417-418.
54. Ravn P, Bidstrup M, Wasnick RD, Davis JW, McClung MR, Balske A, et al. (1999). Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 131:935-942.
55. Rosenberg TJ, Ruggiero S, Mehrotra O, Engroff SL (2003). Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 61(Suppl 1):60.
56. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534.
57. Ruggiero SL, Fantasia J, Carlson E (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433-441.
58. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. (2002). Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8:1080-1084.
59. Sarathy AP, Bourgeois SL, Goodell GG (2005). Bisphosphonateassociated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31:759-763; erratum in J Endod 31:835-836, 2005.
60. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic lesions: a randomized placebocontrolled trial. J Clin Oncol 17:846-854.
61. Tosi P, Zamagni E, Cangini D, Tacchetti P, Offidari M, Ronconi S, et al. (2005). Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid (abstract). Blood 106:3461.
62. United States Food and Drug Administration Oncologic Drugs Advisory Committee (2005). Combidex briefing information. http://www.fda.gov/ohrms/ dockets/ac/05/briefing/2005-4095b1.htm
63. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FS, Beex LV, Blijham G, et al. (1993). Palliative Pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498.
64. Van Poznak C, Ward B (2006). Osteonecrosis of the jaw. Curr Opin Orthop 17:462-468.
65. Vannucchi AM, Ficarra G, Antonioli E, Bosi A (2005). Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br JHaematol 128:738-740.
66. Woo SB, Hellstein JW, Kalmar JR (2006). Narrative corrected review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761; erratum in Ann Intern Med 145:235, 2006.
67. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. (2002). Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 302:1055-1061.